Duloxetine + Placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Osteoarthritis

Conditions

Osteoarthritis

Trial Timeline

Sep 1, 2013 → Jun 1, 2015

NCT ID

NCT01931475

About Duloxetine + Placebo

Duloxetine + Placebo is a phase 3 stage product being developed by Eli Lilly for Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01931475. Target conditions include Osteoarthritis.

What happened to similar drugs?

20 of 20 similar drugs in Osteoarthritis were approved

Approved (20) Terminated (1) Active (0)

✅NISEDr. Reddy's LaboratoriesApproved

✅Duloxetine + Sugar pillEli LillyApproved

✅Capsaicin Topical SolutionAstellas PharmaApproved

✅duloxetineEli LillyApproved

✅ImrecoxibJiangsu Hengrui MedicineApproved

✅Etoricoxib (Arcoxia) + Sugar pillMerckApproved

✅zoledronic acidNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01931475	Phase 3	Completed	Sep 1, 2013	Jun 1, 2015	Osteoarthritis
NCT01451606	Approved	Terminated	Jul 11, 2011	Nov 4, 2015	Pelvis Pain Chronic
NCT01226511	Phase 3	Completed	Jun 1, 2011	Jun 1, 2013	Anxiety Neuroses
NCT01179672	Phase 3	Completed	Apr 1, 2011	Aug 1, 2013	Diabetic Neuropathy, Painful
NCT01237587	Phase 3	Completed	Mar 1, 2011	Nov 28, 2017	Fibromyalgia
NCT01118780	Approved	Completed	Oct 1, 2010	Jul 1, 2012	Generalized Anxiety Disorder
NCT01070329	Approved	Completed	Mar 1, 2010	Mar 1, 2011	Major Depressive Disorder
NCT01000805	Approved	Completed	Nov 1, 2009	Oct 1, 2010	Major Depressive Disorder
NCT01018680	Phase 3	Completed	Nov 1, 2009	Apr 1, 2011	Osteoarthritis Knee Pain
NCT00965081	Approved	Completed	Sep 1, 2009	Nov 1, 2010	Fibromyalgia, Primary
NCT00803361	Phase 3	Completed	Dec 1, 2008	Jan 1, 2010	Generalized Anxiety Disorder
NCT00767806	Phase 3	Completed	Sep 1, 2008	Jul 1, 2009	Chronic Low Back Pain
NCT00433290	Phase 3	Completed	Feb 1, 2007	May 1, 2008	Osteoarthritis Knee Pain
NCT00424593	Phase 3	Completed	Jan 1, 2007	Oct 1, 2008	Back Pain Without Radiation
NCT00457730	Phase 2/3	Completed	Jan 1, 2007	Aug 1, 2012	Multiple Sclerosis
NCT00408876	Phase 3	Completed	Dec 1, 2006	Nov 1, 2007	Back Pain Without Radiation
NCT00408421	Phase 3	Completed	Nov 1, 2006	Oct 1, 2007	Osteoarthritis Knee Pain
NCT00607789	Approved	Completed	Oct 1, 2006	Oct 1, 2009	Binge Eating
NCT00375973	Phase 2/3	Completed	Sep 1, 2006	Mar 1, 2014	Fatigue Syndrome, Chronic
NCT00233025	Phase 3	Completed	Sep 1, 2005	Jun 1, 2007	Fibromyalgia

Competing Products

20 competing products in Osteoarthritis

See all competitors

Product	Company	Stage	Hype Score
NISE	Dr. Reddy's Laboratories	Approved	40
NISELAT	Dr. Reddy's Laboratories	Pre-clinical	23
LY2828360 + Placebo	Eli Lilly	Phase 2	35
Investigational Medical Product (IMP) administered in parent study	Eli Lilly	Phase 3	40
Duloxetine + Sugar pill	Eli Lilly	Approved	43
UBX0101 or placebo	Unity Biotechnology	Pre-clinical	8
UBX0101	Unity Biotechnology	Phase 1	19
UBX0101	Unity Biotechnology	Phase 2	25
UBX0101	Unity Biotechnology	Phase 1	19
YH23537 + Celecoxib + YH23537 placebo	Yuhan	Phase 2	35
Sodium hyaluronate + placebo injection	Daiichi Sankyo	Phase 3	32
ASP7962 + Naproxen + Placebo	Astellas Pharma	Phase 2	35
Capsaicin Topical Solution	Astellas Pharma	Approved	43
CGS-200-1 + CGS-200-5 + CGS-200 Vehicle	Astellas Pharma	Phase 2	35
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo	Sun Pharmaceutical	Phase 2	35
Duloxetine + Placebo	Shionogi	Phase 3	40
Duloxetine	Shionogi	Phase 3	40
ONO-4474 Part A1 + Placebo Part A1 + ONO-4474 Part A2 + Placebo Part A2 + ONO-4474 Part B + Placebo Part B + ONO-4474 Part C + Placebo Part C + ONO-4474 Part D + Placebo Part D	Ono Pharmaceutical	Phase 1	29
ONO-4474 + Placebo matching ONO-4474	Ono Pharmaceutical	Phase 2	27
Duloxetine + Placebo	Eli Lilly	Phase 3	40